PRDX2 and neoplasm: This activity attracts more specific T cells infiltrating into the tumor microenvironment (TME) to comprise the T cell receptor/MHC/TSA complex, eventually activating the immune response and tumor killing effects of CD4+ T cells and CD8+ T cells.